文献速递细菌感染、耐药与抗菌药物

β-内酰胺暴露与MRSA菌血症清除及急性肾损伤的关联:CAMERA2试验事后分析

Association between β-lactam exposure and clearance of bacteraemia and acute kidney injury in patients with methicillin-resistant Staphylococcus aureus bloodstream infections-a post hoc analysis of the CAMERA2 trial.
PubMed 文献 · Clin Microbiol Infect · 2026-04-12

该研究为CAMERA2试验的事后分析,按β-内酰胺使用时机分四组,评估其对耐甲氧西林金黄色葡萄球菌菌血症清除及急性肾损伤的影响。结果显示,各β-内酰胺暴露组菌血症清除均快于未使用组,而AKI风险随暴露时长增加而升高,早期短程暴露AKI风险未见明显增加。

要点

  • 早期短程抗葡萄球菌β-内酰胺可加快MRSA菌血症清除
  • 全程β-内酰胺暴露的AKI风险最高
  • 早期β-内酰胺暴露的AKI风险升高不明显

核心结论

  • β-内酰胺联合治疗对菌血症清除和AKI呈时长依赖性效应,早期短程暴露可加快清除且可能不明显增加肾毒性风险。

研究设计与样本

  • CAMERA2试验事后分析,按β-内酰胺使用时机分为Early、Late、Throughout和None四组,基线需肾脏替代治疗者排除于AKI评估。

主要发现

  • 与无β-内酰胺相比,Early、Late和Throughout组菌血症清除校正HR分别为1.59(1.16-2.19)、1.62(1.14-2.31)和1.85(1.36-2.52)。
  • 与None组相比,Early、Late和Throughout组AKI校正OR分别为1.24(0.27-6.60)、6.01(1.61-29.60)和7.93(2.43-36.30)。

临床怎么用

  • 经验性治疗期短程使用抗葡萄球菌β-内酰胺可能加快MRSA菌血症清除,且不明显增加肾毒性,但需权衡AKI风险。

局限性

  • 为事后分析,分组非随机化,结论需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: In the Combination Antibiotic Therapy for Methicillin-Resistant Staphylococcus aureus (CAMERA2) trial, combination of vancomycin and 7 days of a β-lactam resulted in faster clearance of methicillin-resistant Staphylococcus aureus bacteraemia and higher rates of nephrotoxicity compared with monotherapy. Many participants received empirical β-lactam prior to enrolment. Whether the duration of β-lactam use, including the empiric treatment, impacts clinical and microbiological outcomes is unclear. METHODS: In a post hoc analysis of the CAMERA2 study, we investigated the impact of β-lactam therapy duration on the hazard ratio for clearance of bacteraemia and the odds ratio (OR) for development of acute kidney injury (AKI). β-Lactam use was categorized as 'Early' (any β-lactam for ≥24 hours from time of blood culture collection until trial randomization), 'Late' ([flu]cloxacillin or cefazolin for 7 days, only after randomization), 'Throughout' (Early + Late) or 'None' (<24 hours of any β-lactam). Participants requiring renal replacement therapy at baseline were excluded from assessment of AKI. RESULTS: Compared with no β-lactam treatment (n = 74), 'Early' (n = 104), 'Late' (n = 63) or 'Throughout' (n = 111) β-lactam receipt was associated with adjusted hazard ratios (95% CI) for faster clearance of bacteraemia of 1.59 (1.16-2.19), 1.62 (1.14-2.31) and 1.85 (1.36-2.52), respectively. Compared with 'None' (n = 61), 'Early' (n = 81), 'Late' (n = 52) and 'Throughout' (n = 92) groups had adjusted ORs of AKI of 1.24 (0.27-6.60), 6.01 (1.61-29.60) and 7.93 (2.43-36.30), respectively. CONCLUSIONS: Combination treatment with a β-lactam was associated with a duration-dependent effect on clearance of bacteraemia and AKI. Short-duration antistaphylococcal β-lactam during the empiric treatment period was associated with faster clearance of methicillin-resistant S. aureus bacteraemia, and may not substantially increase the risk of nephrotoxicity.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Petersiel N, Legg A, Ong SWX, et al. Association between β-lactam exposure and clearance of bacteraemia and acute kidney injury in patients with methicillin-resistant Staphylococcus aureus bloodstream infections-a post hoc analysis of the CAMERA2 trial. Clin Microbiol Infect. 2026. PMID: 41974351. doi:10.1016/j.cmi.2026.04.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。